Enhancing repair of myelin is an important but still elusive therapeutic goal in many neurological disorders 1 . In multiple sclerosis, an inflammatory demyelinating disease, endogenous remyelination does occur but is frequently insufficient to restore function. Both parenchymal oligodendrocyte progenitor cells and endogenous adult neural stem cells resident within the subventricular zone are known sources of remyelinating cells 2 . Here we characterize the contribution to remyelination of a subset of adult neural stem cells, identified by their expression of Gli1, a transcriptional effector of the sonic hedgehog pathway. We show that these cells are recruited from the subventricular zone to populate demyelinated lesions in the forebrain but never enter healthy, white matter tracts. Unexpectedly, recruitment of this pool of neural stem cells, and their differentiation into oligodendrocytes, is significantly enhanced by genetic or pharmacological inhibition of Gli1. Importantly, complete inhibition of canonical hedgehog signalling was ineffective, indicating that the role of Gli1 both in augmenting hedgehog signalling and in retarding myelination is specialized. Indeed, inhibition of Gli1 improves the functional outcome in a relapsing/remitting model of experimental autoimmune encephalomyelitis and is neuroprotective. Thus, endogenous neural stem cells can be mobilized for the repair of demyelinated lesions by inhibiting Gli1, identifying a new therapeutic avenue for the treatment of demyelinating disorders.
Remyelination in the adult human and mouse brains is performed by two cell types: oligodendrocyte progenitor cells (OPCs) and neural stem cells (NSCs). OPCs, which are present in the parenchyma of healthy brain as well as in, and around, multiple sclerosis lesions 3 , can be identified by their expression of the NG2 proteoglycan and platelet-derived growth factor receptor alpha (PDGFR-a). They respond locally to demyelination by generating oligodendrocytes although do not migrate long distances during remyelination 4, 5 . NSCs present in the subventricular zone (SVZ), express glial fibrillary acidic protein (GFAP) and Nestin, and are normally quiescent. In response to demyelination, cells in the adult SVZ can generate oligodendrocytes 6 , including, presumptively, in patients with multiple sclerosis 7 .
The signals that activate and recruit NSCs to lesion sites and promote their local differentiation into oligodendrocytes remain poorly understood. A candidate to regulate NSCs is sonic hedgehog (Shh), an important morphogen during CNS development that is required for the generation of most oligodendrocytes during development 8 and for the maintenance of stem cells in the adult SVZ 9 . Shh is therefore an attractive candidate to expand the pool of premyelinating cells available for repair. Indeed, Shh levels have been reported to increase in remyelinating lesions 10 .
Canonical Shh signalling is mediated by interactions of the hedgehog receptor patched (Ptc) with the G-protein-coupled transmembrane co-receptor smoothened (Smo) . Binding of Shh to Ptc relieves its inhibition of Smo and thereby activates the Gli family of zinc-finger transcription factors 11 . Of the three Gli proteins, Gli1 is the only one whose transcription is driven by Shh signalling and its expression is therefore considered a sensitive readout of sustained, high-level activation of this pathway 12, 13 .
In this study, we have examined remyelination by the Shh-responsive (that is, Gli1 1 ) pool of NSCs, which is concentrated in the ventral SVZ and comprises ,25% of NSCs 14 . To genetically fate-map Gli1 1 NSCs, we crossed Gli1 CreERT2/1 mice with the Rosa-CAG-EGFP (RCE) reporter 15 to generate Gli1 CE mice in which tamoxifen treatment results in permanent expression of cytoplasmic green fluorescent protein (GFP) in all Gli1-expressing cells and their progeny 12, 14 ; see Supplementary Table 1 for a summary of these and other mouse lines used in this study. GFP-labelled cells correspond to NSCs in the SVZ and a subset of astrocytes, but not OPCs or oligodendrocytes. We then followed the fate of these GFP 1 cells after inducing demyelination in the mouse corpus callosum (CC) either by (1) dietary cuprizone 16 or (2) direct, stereotactic injection of the detergent lysophosphatidyl-choline (LPC) 4 .
At 6 weeks of dietary cuprizone, corresponding to peak demyelination, GFP-expressing cells were recruited to areas of demyelination. In contrast, no labelled cells were observed in the CC of controls ( Fig. 1a ). At 2 weeks of remyelination, after removal of cuprizone from the diet, GFPexpressing cells in the CC (17.3 cells 6 2.6 per section) differentiated exclusively into glia, primarily oligodendroglia, namely PDGFR-a 1 OPCs (9.8 6 8.7%) and CC1 1 oligodendrocytes (40.2 6 15.1%), as well as GFAP-expressing astrocytes (15.5 6 4.1%, Fig. 1b , c); other markers are shown in Extended Data Fig. 1a . Approximately 30% of the GFP 1 cells in the CC remained unspecified at this time. None of the GFP-labelled cells expressed neuronal (NeuN) or microglial (Iba1 and CD11b) markers (data not shown). Ten weeks after recovery from cuprizone diet, the numbers of GFP 1 cells in the demyelinated CC increased from about 17 to 48 cells per section and consisted of PDGFR-a 1 OPCs (18.4 6 1.8%), CC1 1 oligodendrocytes (58.3 6 5.3%) and GFAP 1 astrocytes (28.7 6 11.6%) ( Fig. 1c) , accounting for all the GFP 1 cells in the CC. These results suggest that Gli1 1 NSCs continue to generate glial cells in the CC for a prolonged period after demyelination. In addition to the cells within the CC, GFP-labelled cells located outside the CC frequently increased with demyelination; these correspond to a subset of protoplasmic astrocytes that are responsive to Shh 17 .
The newly generated, NSC-derived oligodendrocytes remyelinated axons, as evidenced by GFP-labelled processes that flanked nodes of Ranvier ( Fig. 1e ), overlapped with the paranodal marker Caspr (Extended Data Fig. 1b ), and co-expressed myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP), but not the Schwann cell myelin protein P0 (Extended Data Fig. 1b ). Immunoelectron microscopy of the CC in Gli1 CreERT2/1 mice crossed to a membrane GFP reporter (Rosa-TdTomato-mGFP) demonstrated GFP labelling in compact myelin sheaths surrounding axons ( Fig. 1e ), corroborating that these NSCs form remyelinating oligodendrocytes.
For comparison, we also fate-mapped the entire pool of NSCs, in healthy brains and after demyelination using a Nestin CE/1 driver line that preferentially labels the SVZ 18 (Fig. 1b ). We also observed GFP 1 cells outside the SVZ, including some cells within the healthy CC (Fig. 1b ). The cells present in the healthy CC were largely astrocytes (93.81 6 3.34%); a small proportion were OPCs (1.81 6 1.57%) and oligodendrocytes (4.42 6 0.29%) ( Fig. 1b, d ). Two weeks after recovery from cuprizone, there was a striking increase in the numbers of labelled cells in the CC, consistent with a recent report 2 , associated with an increase in the percentages of OPCs (28.49 6 18.52%) and oligodendrocytes (9.35 6 3.25%) and a commensurate reduction in the proportion of astrocytes (59.72 6 9.54%) ( Fig. 1b, d ). These results do not distinguish whether the oligodendrocytes present in the CC during remyelination were generated primarily from NSCs, from pre-existing precursors within the CC or both. They emphasize that, in contrast to the broader Nestin 1 pool of NSCs, Gli1 demarcates a distinct set of NSCs in the SVZ that are recruited only upon demyelination and preferentially fated to oligodendroglia.
To assess whether cells that enter demyelinated lesions in the CC were actively responding to Shh, we analysed Gli1 expression using Gli1 nLacZ mice, which express nuclear LacZ from the Gli1 locus 19 . In healthy brains, Gli1 was expressed by cells in the cortex, basal forebrain and ventral SVZ (Extended Data Fig. 2a, b ). NSCs that co-expressed GFAP and Gli1 were also present in the human SVZ (Extended Data Fig. 2c ). Outside the SVZ, labelled cells co-expressed GFAP (data not shown) but not PDGFR-a (Extended Data Fig. 2b ) and thus correspond to a subset of mature astrocytes but not OPCs, as previously reported 17 . No LacZ 1 cells were present in the CC during or after recovery from cuprizone-or LPC-mediated demyelination (data not shown), further indicating that Shh-responsive cells do not arise from within the callosum. Thus, although NSCs in the SVZ actively respond to Shh, their progeny, upon entry into the callosum, do not. These results are consistent with the minimal expression of Gli proteins by OPCs or oligodendrocytes during development (http://web.stanford.edu/group/barres_lab/brain_rnaseq. html) and indicate Shh signalling is decreased in OPCs during both normal development and active remyelination.
A time-course analysis of fate-mapped cells in Gli1 CE/1 mice strongly suggests NSCs emigrate from the SVZ into the CC after demyelination (Extended Data Fig. 2d -f) and argues against transdifferentiation of Gli1-expressing astrocytes in the cortex as a source of labelled cells. Together, these data indicate that a Shh-responsive pool of NSCs in the SVZ are recruited specifically to the demyelinated CC where they downregulate Gli1 and differentiate into mature, myelinating oligodendrocytes. Downregulation of Gli1 expression by remyelinating SVZ-derived OPCs raised the possibility that inhibiting Shh signalling might further augment remyelination-a notion that contrasts with previous studies showing that Shh signalling can promote repair after CNS injury 20 and is required for remyelination 10 . We first analysed the effects of a partial loss of Shh signalling by fate mapping NSCs in Gli1 null (Gli1 CE/nLacZ ;RCE) versus heterozygous (Gli1 CE/1 ;RCE) mice. Consistent with our hypothesis, there were many more GFP-labelled cells in the remyelinating CC of Gli1 nulls (63 6 6.5 per section) than in Gli1 heterozygotes (17.3 6 2.6 per section, Fig. 2a, b) , and a much higher percentage of these were mature oligodendrocytes in the nulls (81.3 6 4.4%) than in the heterozygotes (40.2 6 15.1%, Fig. 2c ). Overall, there were , 7.5-fold more GFP-labelled, mature oligodendrocytes in the Gli1 null versus heterozygotes mice. The proportion of labelled OPCs in the nulls versus heterozygotes was similar (5.226 2.5% versus 9.8 6 8.7%, Fig. 2c ) whereas that of GFAP-expressing astrocytes was significantly reduced (2.6 6 1.3% versus 15.5 6 4.1%, Fig. 2c ). Finally, overall myelin levels in the CC were increased in the Gli1 nulls compared with heterozygotes 3 weeks after cessation of cuprizone ( Fig. 2d ), strongly suggesting this enhanced NSC remyelination is physiologically significant. 
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While cuprizone primarily demyelinates the CC, it also has modest effects on other white matter tracts 16 . Accordingly, labelled oligodendrocytes in the Gli1 nulls were also present in white matter tracts at sites distant from the SVZ including the lateral striatum, anterior commissure (Extended Data Fig. 3a , b) and the optic nerve (data not shown). No GFP-labelled cells were seen in the CC or other white matter tracts of heterozygotes or nulls on a control diet ( Fig. 2a ). Thus, in the adult, this effect of Gli1 is specific to remyelination.
Myelination also started significantly earlier in the Gli1 nulls than in the heterozygotes (Extended Data Fig. 4a, b ). In addition, the CC were slightly larger on average in the adult Gli1 nulls versus heterozygotes on the basis of Black-Gold myelin staining (Extended Data Fig. 4c-e ), although differences were not statistically significant. Thus, during development, Gli1 expression delays the onset of myelination and in the adult substantially inhibits remyelination by the Shh-responsive NSCs.
As Gli1 is expressed only upon sustained, high-level Shh signalling, we asked whether complete abrogation of this pathway also enhanced myelination. In contrast to loss of Gli1, loss of canonical Shh signalling by conditional ablation of smoothened in Gli1-expressing NSCs (Gli1 CE/1 ;Smo fx/fx ;RCE mice) did not increase the numbers of labelled cells in the CC or alter their cell fates ( Fig. 2a-c) . Thus, loss of Gli1 is distinct from loss of Shh signalling, emphasizing the specificity of the effects of Gli1.
We also examined the effects of activating canonical Shh signalling in the presence or absence of Gli1. To this end, we expressed an activated (M2) form of Smo 21 in NSCs upon tamoxifen treatment in Gli1 heterozygous (Gli1 CE/1 ;Smo M2 ) and null (Gli1 CE/nLacZ ;Smo M2 ) mice; the activated SmoM2 allele is itself fused to yellow fluorescent protein, allowing fate mapping. Again, labelled cells were only detected in the CC in mice that had undergone demyelination (Extended Data Fig. 5a ). In the Gli1 CE/1 ;Smo M2 mice, many of the GFP 1 cells (5.6 6 2.9 per section) in the CC (Extended Data Fig. 5b ) were oligodendrocyte progenitors (57.5 6 23.2%, Extended Data Fig. 5c ), a much higher proportion than in Gli1 CE/1 mice (9.8 6 8.7%). These results agree with previous studies that showed that increasing the levels of Shh in the brain enhances the generation of OPCs but blocks their maturation 22 . The Gli1 null ;Smo M2 mice had many more GFP 1labelled cells in the CC than the Gli1 het ;Smo M2 mice (47.2 6 25.7 versus 5.6 6 2.9 per section, Extended Data Fig. 5b ) and a significantly greater proportion of these were mature oligodendrocytes (52.5 6 10.5% versus 28.8 6 3.8%). On average, the Gli1 null ;Smo M2 mice had ,16 times as many oligodendrocytes derived from the Shh-responsive NSC pool than the Gli1 het ;Smo M2 mice (Extended Data Fig. 5b , c). These results indicate loss of Gli1 has an even greater effect in the context of active Shh signalling, promoting robust recruitment and relieving an arrest of NSCs differentiation into oligodendrocytes in the remyelinating CC.
Other analyses revealed that loss of Gli1 results in a significant increase in proliferation in Shh-responsive SVZ NSCs but only at the onset of demyelination, namely 3 weeks of cuprizone treatment (Extended Data Fig. 6a, b ). There was no difference in the proliferation of NSCs of Gli1 nulls versus heterozygotes on a normal diet, on a cuprizone diet at 4, 5 or 6 weeks or 2 weeks after removal of cuprizone (data not shown). The higher proliferation at 3 weeks may contribute to preservation of the stem-cell pool, which was unchanged in the SVZ of Gli1 nulls (see Extended Data Fig. 6c ). We did not detect any increase in Shh levels with demyelination or a significant difference in Shh levels between Gli1 heterozygotes versus nulls (Extended Data Fig. 6d-f ). Thus, the major effects of loss of Gli1 in NSCs appear to be enhanced differentiation and recruitment to lesion sites and an increase in proliferation during demyelination.
These findings suggested that Gli1 might be a useful therapeutic target to promote remyelination. To test this possibility, we infused GANT61, a small molecule inhibitor of Gli1 23 into the lateral ventricle of Gli1 CE/1 mice via a mini-osmotic pump; we corroborated inhibition of Gli1 by the reduction of its messenger RNA (mRNA) levels by quantitative PCR (qPCR) (Extended Data Fig. 7a ). A similar inhibition of Gli1 mRNA levels was observed when the drug was administered by intraperitoneal injection and oral gavage, indicating GANT61 can cross the blood-brain barrier efficiently. We infused GANT61 in Gli1 CE/1 mice during the last 2 weeks of the cuprizone diet and continued it for an additional 2 weeks off cuprizone for a total of 4 weeks. Mice that received GANT61 versus vehicle had significantly greater numbers of labelled cells (43.8 6 22.1 versus 6.4 6 5 per section, and differentiation during remyelination. a, Gli1 1 cells were fate-mapped in cuprizone-fed Gli1 CE/1 (Gli1 Het ) mice treated with vehicle or GANT61 for 4 weeks before analysis. Mice that received GANT61 had more GFP 1 cells than those receiving vehicle. N 5 5 mice per group. Scale bar, 50 mm. b, c, Mice that received GANT61 had an approximately sevenfold increase in the numbers of GFP-labelled cells in the CC (b) and a significant increase in the percentage of mature oligodendrocytes (c). d, Wild-type mice were fed a cuprizone diet and treated with vehicle or GANT61 for 9 weeks. The brains were examined 6 weeks after recovery from cuprizone diet. Mice that received GANT61 showed significantly higher MBP fluorescence intensity levels than vehicle-treated mice. N 5 5 mice per group. Data are mean 6 s.e.m., Student's t-test. Fig. 3a, b) and a significantly greater proportion of these were oligodendrocytes (65.4 6 7.5% versus 21.4 6 18.7%, Fig. 3c ). Administration of GANT61 was well tolerated and did not deplete the NSCs in the SVZ (Extended Data Fig. 7b, c) . Importantly, mice receiving extended treatment with GANT61, namely during the last 3 weeks of the cuprizone diet and 6 weeks thereafter for a total of 9 weeks, had more myelin in the CC than mice similarly treated with vehicle ( Fig. 3d) . Thus, the Gli1 inhibitor enhanced the recruitment and differentiation of Shh-responsive NSCs into oligodendrocytes at sites of demyelination, promoting remyelination. These effects of GANT61 are specific to NSCs as there were no effects on remyelination by OPCs on the basis of their fate mapping in NG2 CreERT2 transgenic mice 24 crossed to the RCE reporter (Extended Data Fig. 8 ). The lack of an effect of GANT61 on OPC remyelination is consistent with the absence of Gli1 expression by these cells. These results also indicate that enhanced repair by NSCs resulting from GANT61 treatment does not come at the expense of OPC remyelination: rather, it is additive.
To address the therapeutic potential of inhibiting Gli1, we examined the effects of GANT61 in a relapsing-remitting model of experimental autoimmune encephalitis (RR-EAE), a physiologically relevant model of inflammatory demyelination and remyelination. In this model, RR-EAE is induced by injecting proteolipid protein (PLP) peptide into wild-type SJL mice 25 ; the severity of the clinical phenotype of the initial attack correlates with the extent of spinal cord inflammation, whereas the late-stage neurological disability in later relapses correlates with axonal loss 26 probably resulting from cumulative injury including chronic demyelination. GANT61 was administered by daily oral gavage either prophylactically (that is, at the onset of PLP immunization) or therapeutically (that is, at the onset of symptoms). Neither treatment protocol altered the induction of EAE or the severity of the acute attack (about day 12), suggesting GANT61 did not affect the immune response (Fig. 4a ). In agreement, Gli1 was not expressed by cells in the lymphocytic or monocytic lineages isolated from the spleen, thymus or liver of healthy (Extended Data Fig. 9 ) or cuprizone-treated mice (data not shown).
Of note, GANT61 reduced the severity of the first relapse (around day 27) and significantly enhanced functional recovery during and after the second relapse (around day 46) compared with vehicle treatment ( Fig. 4a ). We therefore examined myelin levels, axon pathology and motor neuron numbers in the (prophylactic, therapeutic) GANT61-and vehicle-treated lumbar spinal cords at the end of the second relapse phase (that is, day 53). In electron microscopy images, all three groups had significant spinal cord pathology, with disruption of fascicles of myelinated axons and pathology of individual myelinated axons most evident in vehicle-treated compared with the GANT61-treated groups (Fig. 4b, c) . In all EAE groups, pathology was most pronounced in small-diameter axons (,0.5 mm, Extended Data Fig. 10a-c) which were increased in numbers and had significantly lower G ratios (ratio of axon diameter to myelinated axon diameter); the reduction in axon diameter and corresponding increase in G ratios are probably due to axonal atrophy and suggestive of active demyelination 27 . We did not detect significant numbers of unmyelinated or thinly myelinated axons in any group (Extended Data Fig.  10a-c) . While thin myelin sheaths have long been considered the hallmark of remyelination 1 , recent studies suggest remyelination performed by neural stem cells 2 or in the spinal cord can be of normal thickness 28 . Analysis of MBP levels supported significantly higher levels of myelin in the drug-versus vehicle-treated groups (Fig. 4f) .
The numbers of lower motor neurons, identified by co-staining for NeuN and choline acetyltransferase (ChAT) 29 
model without altering the immune response. Gli1 is primarily expressed in the spinal cord by a subset of astrocytes within the parenchymal grey matter and by cells located around the central canal, a site of spinal cord NSCs 30 but not by NG2 1 OPCs (Extended Data Fig. 10d ). These findings suggest the effects of inhibiting Gli1 on myelination and neuroprotection are mediated by direct effects on neural stem cells or potentially by indirect effects mediated by parenchymal astrocytes.
These studies demonstrate that inhibiting Gli1 appears to be a welltolerated and effective strategy for mobilizing and enhancing the differentiation of a resident population of Shh-responsive neural stem cells. The findings of elevated levels of myelin, reduced axon pathology and preservation of lower motor neurons in a RR-EAE model further support its therapeutic potential. This approach may therefore be useful in aiding repair in multiple sclerosis and other demyelinating neurological disorders. The findings also highlight that different pools of remyelinating cells (that is, NSCs and OPCs) might require different strategies to promote their remyelination of axons, raising the possibility of using combinatorial strategies to enhance repair.
METHODS
No statistical methods were used to predetermine sample size. Fate mapping and demyelination. Ten-week-old mice were administered 5 mg tamoxifen (Sigma) in corn oil on alternate days for a total of four intraperitoneal injections. Table 1 ). No labelling was seen in the absence of tamoxifen administration. For the LPC model, 2 ml of 1% LPC (Calbiochem) were stereotaxically injected into the CC at 1.5 mm anterior, 1.2 mm lateral and 2.2 mm ventral to the bregma. Drug administration. GANT61 (Enzo Life Sciences) (5.6 mg kg 21 per day) or vehicle (50% DMSO 1 15% ethanol in PEG400) were delivered via mini-osmotic pump (model 2004, Durect) at a rate of 0.25 ml h 21 for 4 weeks into the lateral ventricle of Gli1 CE/1 mice at 0.5 mm anterior, 0.75 mm lateral and 2.5 mm ventral to the bregma. For intraperitoneal and oral routes, 50 mg kg 21 GANT61 dissolved in ethanol:corn oil (1:4) was administered daily for 4 weeks.
Immunostaining. For Black-Gold (Millipore) myelin staining, mice were perfused with 4% PFA, and 20 mm coronal cryosections were stained according to the manufacturer's protocol. For all other analyses, mice were perfused with Prefer (Anatech) and 20 mm coronal cryosections were processed for immunofluorescence with rabbit or chicken anti-GFP (1:1,000, Invitrogen) and one of the following antibodies: rat anti-PDGFR-a (1:200, BD Biosciences); rabbit anti-NG2 (1:200, Millipore), anti-S100b (1:600, Dako) and b4-spectrin (1:4,000, from M. Rasband); mouse anti-CC1 (1:400, Calbiochem), anti-GFAP (1:400, Sigma), anti-NeuN (1:200, Millipore), anti-Shh (1:500, DSHB), anti-MOG (1:50, Sigma) and anti-MBP (1:500, Millipore); goat anti-LacZ (1:2,000, Biolegend) and anti-ChAT (1:200, Millipore); chicken anti-P0 (1:200, Millipore); guinea pig anti-Caspr (1:3,000, from M. Bhat) and anti-Sox10 (1:1,000, from M. Wegner). Cryosections (30 mm) of an autopsy specimen of a healthy human brain (provided by New York Brain Bank of Columbia University) were stained with rabbit anti-Gli1 (1:2,000, Abcam) and mouse anti-GFAP (1:400, Sigma). Secondary antibodies were goat or donkey anti-species conjugated with Alexafluors (1:1,000, Molecular Probes). Nuclei were counterstained with Hoechst 33258 (1:5,000, Invitrogen). Fluorescent images were obtained as Z-stacks of 1 mm optical sections using a confocal laser-scanning microscope (LSM 510, Zeiss) and processed using Adobe Photoshop. At least ten sections per mouse were analysed and data from three to five mice were combined to determine the average and standard deviation. The investigators were blinded to allocation during experiments and outcome assessment. Student's t-test was performed to calculate P values.
Flow cytometry. Cells from the thymus, spleen and liver were stained with the following conjugated antibodies: CD4 (RM4-5), CD8 (53-6.7), CD19 (6D5), Ly6c (HK1.4), CD11b (M1/70), CD11c (N418), CD45 (30-F11), PDCA-1 (927), B220 (RA3-6B2) and CD3 (145-2C11). Antibodies were purchased from eBioscience or Biolegend and the staining was performed according to the manufacturer's instructions. DAPI (Invitrogen) was always used to exclude dead cells from the analysis. Stained cells were analysed on a LSRII flow cytometer (BD) and data processed using FlowJo (Tree Star). The investigators were blinded to the genotype of the cells being sorted. EdU labelling. EdU (Invitrogen; 200 mg kg 21 ) dissolved in saline was administered by intraperitoneal injection 1 day before harvesting the brains. EdU was visualized using the AlexaFluor-594 Click-iT EdU Cell Proliferation Assay Kit (Invitrogen) according to the manufacturer's instructions. EAE model. The EAE experiments were randomized. The PLP-induced EAE model was performed and scored using the EAE induction kit (Hooke Labs) on 8-week-old female SJL mice according to the manufacturer's instructions. We used a random number generator to assign each mouse to a group and used an inclusion criteria of clinical score of 2 or above for final analysis (N 5 9 per group). Mice received either vehicle (ethanol:corn oil (1:4)) or 50 mg kg 21 GANT61 via oral gavage until the end of the experiment, namely day 53 after induction. Separate investigators performed the clinical scoring and the drug treatments and were blinded to each other; the histological analysis was also done blinded. Electron microscopy. Immunoelectron microscopy was performed on brain sections to detect mGFP in the myelin wraps around axons in the CC according to a previous study 32 . The investigators were blinded to allocation during experiments and outcome assessment. qPCR. mRNA was extracted from the forebrains of three mice in each group using RNeasy kit (Qiagen) and reverse-transcribed to complementary DNA using quantitect kit (Qiagen). Power SYBR Green QPCR Master Mix (Applied Biosystems) was used to perform qPCRs in a Stratagene MX3000P thermal cycler. Primers used were Gli1 (forward, 59-CCC ATA GGG TCT CGG GGT CTC AAA C-39; reverse, 59-GGA GGA CCT GCG GCT GAC TGT GTA A-39), Gli2 (forward, 59-AGA GAC AGC AGA AGC TAT GCC CAA-39; reverse, 59-TGG GCA GCC TCC ATT CTG TTC ATA-39) and GAPDH (forward, 59-GGT GTG AAC GGA TTT GGC CGT ATT G-39; reverse, 59-CCG TTG AAT TTG CCG TGA GTG GAG T-39). The 2 2DDCt method was used to analyse the relative gene expressions and Student's t-test was used to calculate P values. 
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Extended Data Figure 7 | GANT61 reduces Gli1 levels but does not deplete neural stem cells in the SVZ. a, Relative expression of Gli1 and Gli2 mRNA in the forebrain of Gli1 CE/1 mice was examined by qPCR after administration of GANT61 (50 mg/kg/day) for 4 weeks. GANT61 decreases the mRNA levels of Gli1 significantly without changing Gli2 levels. N 5 3 mice per group. Data are mean 6 s.e.m., Student's t-test. b, c, The numbers of fate-mapped Gli1 1 neural stem cells in the SVZ were analysed by immunofluorescence as the proportion of GFP 1 cells co-expressing GFAP in Gli1 CE/1 mice treated with vehicle or GANT61 at 2 weeks of recovery from cuprizone diet (b). The percentage of GFAP 1 GFP 1 cells in the SVZ of mice treated with GANT61 was comparable to those treated with vehicle, suggesting that the stem cell pool is not depleted by GANT61 (c). 
Extended Data Figure 9 | Gli1 is not expressed by immune cells of spleen, thymus and liver of healthy mice. a-d, Cells from the spleen, liver and thymus of tamoxifen-treated Gli1 Het (Gli1 CE/1 ) and Gli1 Null (Gli1 CE/nLacZ ) mice were analysed by flow cytometry for GFP expression. Wild-type mice did not express GFP and were used as controls. Representative flow cytometry scatter plots showing absence of GFP expression in CD45 1 /CD3 1 /CD4 1 /CD19 1 T and B cells (a), CD45 1 /CD3 2 /CD19 2 /B220 1 /MPDCA 1 plasmacytoid dendritic cells (b), CD45 1 /CD3 2 /CD19 2 /B220 2 /CD11b 1 macrophages, monocytes, dendritic and natural killer (NK) cells (c) and CD45 1 /CD3 2 /CD19 2 /B220 2 / CD11b 2 cells (d) in Gli1 CE/1 and Gli1 CE/nLacZ mice. N 5 3 mice per genotype. LETTER RESEARCH
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